- The disease
- Surgical scars form when the skin heals after an incision, and in some patients the resulting scar is raised, discoloured, or symptomatic. Abnormal scarring can cause pain, restrict movement, and have cosmetic consequences. Current management options include silicone gels, pressure garments, corticosteroid injections, and laser therapy, but none has established universal efficacy across scar types. There is no globally approved pharmacological agent specifically indicated for the prevention of post-surgical scars.
- What the asset is trying to do
- CACIPLIQ20 contains OTR4120, a synthetic molecule designed to mimic heparan sulfate, a naturally occurring sugar chain found in the tissue matrix. Heparan sulfate normally helps organise growth factors and repair signals in tissue; the company describes CACIPLIQ20 as a ReGeneraTing Agent (RGTA) that aims to restore this microenvironment after injury. Unlike topical steroids or silicone-based products, which act on inflammation or moisture retention respectively, CACIPLIQ20 is intended to interact directly with the structural scaffolding of the tissue. The precise molecular target has not been disclosed publicly (per available input data).
- What the trial is measuring, and why it matters
- The Phase 3 trial (NCT05528328) is a randomised, double-blind, placebo-controlled study enrolling up to 50 patients with post-surgical scars (per ClinicalTrials.gov NCT05528328). The trial compares CACIPLIQ20 against a saline placebo. Scar assessment endpoints in trials of this type typically include validated scales such as the Patient and Observer Scar Assessment Scale (POSAS) or the Vancouver Scar Scale, though the specific primary endpoint for NCT05528328 is (not disclosed in available data). Placebo control in a double-blind design helps isolate the treatment effect from the natural improvement in scars over time.
- Efficacy benchmarks in this setting
- There is no globally approved pharmacological therapy with a labelled indication for prevention of post-surgical scarring against which a direct benchmark can be drawn. In published randomised trials of topical silicone gel for post-surgical scars, Mustoe et al (Plast Reconstr Surg, 2002) reported that silicone products reduced scar scores in some patient populations, though effect sizes and scales varied across studies. Intralesional corticosteroid injections have shown response rates of approximately 50-100% for keloid scars in some series, though methodologies differ widely (per Gold et al, J Clin Aesthet Dermatol, 2014). Early-stage or single-arm figures for CACIPLIQ20 are not statistically comparable to these historical controls given differences in study design, patient selection, and endpoints.
- Commercial context
- No pharmacological product is approved by the US FDA or EMA with a specific indication for the prevention of post-surgical scarring as of the available data. CACIPLIQ20 holds no disclosed regulatory designations (per input data). Tissue Repair (ASX: TRP) has additional CACIPLIQ20 trials underway or completed in chronic wounds (NCT05170984, target 191 patients) and epidermolysis bullosa (NCT06007235, target 16 patients), and a separate compound, OTR4132, is in a Phase 2 stroke trial (NCT06700824) (per ClinicalTrials.gov). No licensing deals, partnership terms, or manufacturing arrangements have been publicly disclosed in the announcements provided.